Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covidien appoints Bayer's Trudeau president of pharma

This article was originally published in Scrip

Executive Summary

Covidien has appointed Mark Trudeau president of its pharmaceuticals segment and a senior vice-president of the company, effective 1 February. With 25 years' experience of the pharmaceutical industry, Mr Trudeau is currently president and CEO of Bayer Healthcare. He has also served in various positions at Bristol-Myers Squibb, Abbott Laboratories and Lilly. Mr Trudeau succeeds Matthew Harbaugh who served as interim president since 2010 when Timothy Wright resigned, and will continue his role as CFO.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016052

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel